Welcome to our dedicated page for Halozyme Thrp news (Ticker: HALO), a resource for investors and traders seeking the latest updates and insights on Halozyme Thrp stock.
Halozyme Therapeutics, Inc. (HALO) generates news that spans drug delivery technology, clinical applications, strategic collaborations and corporate finance. As a biopharmaceutical company focused on subcutaneous administration of biologics, Halozyme’s announcements often highlight how its ENHANZE and Hypercon platforms are being integrated into partner therapies and new indications.
News items frequently cover collaboration and license agreements with global pharmaceutical and biotechnology companies. Examples include agreements with Takeda to use ENHANZE with vedolizumab and with Merus to develop a subcutaneous formulation of petosemtamab. These stories typically describe upfront payments, potential milestones and royalty structures, as well as the therapeutic areas targeted by ENHANZE-enabled products.
Another major category of HALO news involves regulatory milestones achieved by partner products that incorporate Halozyme technologies. Recent press releases describe U.S. Food and Drug Administration approvals for DARZALEX Faspro and RYBREVANT FASPRO, both co-formulated with ENHANZE, in multiple myeloma and EGFR-mutated non-small cell lung cancer. Such updates provide insight into how Halozyme’s platforms translate into commercial products and expanded indications.
Halozyme also issues updates on intellectual property and legal matters, including patent enforcement actions related to its MDASE portfolio and court decisions affecting subcutaneous formulations of other companies’ drugs. In addition, investors can follow corporate developments such as acquisitions, including the purchase of Elektrofi and its Hypercon technology, board appointments, executive transitions and participation in healthcare conferences.
For investors and industry observers, the HALO news feed offers a way to track the evolution of Halozyme’s partnership base, the progress of ENHANZE- and Hypercon-enabled products, and key events that may influence the company’s royalty outlook and strategic direction.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced Dr. Helen Torley's participation at the 2022 Wells Fargo Healthcare Conference from September 7-9, 2022, in Boston, MA. Dr. Torley will present on September 8 at 5:35 a.m. PT / 8:35 a.m. ET, alongside hosting investor meetings. A live audio webcast of the presentation will be available on the Company’s Investor Relations section, with replays accessible for 90 days post-conference. Halozyme is renowned for its ENHANZE® technology, enhancing drug delivery and improving patient experiences.
Halozyme Therapeutics (NASDAQ: HALO) announced the pricing of a $625 million offering of convertible senior notes due 2028, upsized from an initial $500 million. The notes will bear an interest rate of 1.00% and are convertible at a rate of 17.8517 shares per $1,000 principal amount, equating to an initial conversion price of $56.02. Proceeds of approximately $608.7 million will be used for capped call transactions, repurchasing existing convertible notes, and share repurchases, among other corporate purposes, set to close on August 18, 2022.
Halozyme Therapeutics plans a $500 million offering of convertible senior notes due 2028, subject to market conditions, with an option for an additional $75 million. The company intends to use proceeds for capped call transactions, repurchasing shares up to $200 million, and repaying a $250 million term loan due 2026. The offering could potentially influence the market price of Halozyme's common stock.
Halozyme Therapeutics (HALO) announced its second quarter financial results for 2022, reporting a revenue increase of 12% year-over-year to $152.4 million. GAAP diluted EPS was $0.16, while non-GAAP EPS reached $0.53. The company raised its full-year revenue guidance to $655 million to $685 million, driven by strong royalty growth of 86% to $85.3 million and the recent acquisition of Antares Pharma. However, projected operating income and GAAP net income guidance decreased significantly due to acquisition-related costs. Halozyme remains optimistic about future growth with multiple upcoming product launches.
Halozyme Therapeutics (NASDAQ: HALO) announced positive results from Roche's Phase III IMscin001 study, evaluating a subcutaneous formulation of Tecentriq® using ENHANZE® technology. The study demonstrated non-inferior pharmacokinetics of Tecentriq when delivered subcutaneously compared to intravenous infusion in patients with advanced non-small cell lung cancer. Treatment time was significantly reduced to 3-8 minutes versus 30-60 minutes for IV. Roche plans to submit data for global regulatory approval.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced it will release its second quarter 2022 financial results on August 9, 2022, after market close. A conference call will follow at 4:30 p.m. ET with dial-in numbers provided for both domestic and international callers. Halozyme is recognized for its ENHANZE® technology, enhancing drug delivery. With over 600,000 patients impacted, it has commercial products and partnerships with major pharmaceutical companies. For more details, visit www.halozyme.com.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced that CEO Dr. Helen Torley will present at the Goldman Sachs 43rd Annual Global Healthcare Conference from June 14-16, 2022 in Rancho Palos Verdes, CA. Her presentation is scheduled for June 15, 2022, at 8:00 a.m. PT / 11:00 a.m. ET. The event will feature a fireside chat format and one-on-one meetings. A live audio webcast will be accessible via the Investor Relations section of Halozyme’s website and will be available for replay for 90 days.
Halozyme Therapeutics announced the commercial launch of TLANDO™ (testosterone undecanoate), an oral treatment for testosterone replacement therapy, on June 7, 2022. TLANDO was approved by the FDA on March 28, 2022. This launch follows the introduction of XYOSTED in 2018, marking Halozyme's second product in this category. Executives emphasized that TLANDO provides a convenient dosing option requiring no titration, targeting the growing market of male hypogonadism, estimated to affect 30-50% of men with obesity or type 2 diabetes.
Halozyme Therapeutics has successfully completed its acquisition of Antares Pharma, finalizing the payment for shares tendered at $5.60 each. This strategic acquisition aims to enhance Halozyme's capabilities in biopharmaceutical development, particularly through its proprietary ENHANZE® technology, which aims to improve patient treatment experiences. Antares, now a wholly-owned subsidiary, will cease trading on NASDAQ following this merger. Financial advisors included BofA Securities and Wells Fargo, confirming the significant market interest in this consolidation.
Halozyme Therapeutics announced the expiration of the waiting period under the HSR Act for its acquisition of Antares Pharma. The tender offer commenced on April 26, 2022, at a price of $5.60 per share. The offer's completion is contingent upon the tendering of a majority of Antares shares and other customary conditions. The offer is set to expire on May 23, 2022, unless extended. This acquisition aims to enhance Halozyme's innovative therapy offerings, leveraging Antares' expertise in drug delivery systems.
FAQ
What is the current stock price of Halozyme Thrp (HALO)?
What is the market cap of Halozyme Thrp (HALO)?
